UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results, Provides Corporate Updates

• Following recent transactions and cost-saving measures, Sol-Gel’s cash flow is expected to extend into the first quarter of 2026
• Ongoing Phase 3 clinical trial of SGT-610 for Gorlin syndrome with over 30 activated clinical sites; topline results expected in Q2 2026
• The proof-of-concept study of SGT-210 in patients with Darier’s disease, a significant unmet medical need in dermatology, is still ongoing
• Sol-Gel sells its rights to the Abbreviated New Drug Application (ANDA) drug product generic to Zoryve Cream (roflumilast cream 0.3%)
• Following a management restructuring, Mr. Mori Arkin, the Company’s Executive Chairman and controlling shareholder, will be appointed as interim CEO of the Company effective January 1, 2025, subject to shareholder approval.
• Sol-Gel has recently signed licensing agreements for TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional licensing agreements in Latin America and other territories

NESS ZIONA, Israel, August 17, 2024 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with serious skin conditions, conducting a Phase 3 clinical trial with SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and two approved broad category dermatology products, TWYNEO and EPSOLAY, today announced financial results for the second quarter ended June 30, 2024 and provided a business update.

Q2 2024 and recent company information Developments